Positive in vivo CAR-EV data in TNBC

INOVIQ Limited (ASX: IIQ) (INOVIQ or the Company) is pleased to announce positive in vivo proof-ofconcept (PoC) data demonstrating the therapeutic potential of its proprietary Epidermal Growth Factor Receptor (EGFR)-targeted chimeric antigen receptor (CAR)-Natural Killer (NK)-extracellular vesicles (EVs or exosomes) in a triple-negative breast cancer (TNBC) mouse model. These results highlight the